Study On The Effect Of Human NSCLC Cell With The Conjoin Of Cinobufotalin And Gemcitabine

Objective: we will use cinobufotalin and gemcitabine to investigate the human NSCLC HCC827 cell by the subcultureing ? drug sensitive test of the thiazolylblu and flow cytometry, to assay tumor cell apoptosis and cell line. By this way,we hope to approach the designation in curing human NSCLC, the influence of its suppression ratio and cell line. Furthermore,we wish to detect the theoretical basis for the cinobufotalin to become the assistant medicament in treating human NSCLC. Methods : Experience group We utilizate the cinobufotalin and gemcitabine to investigate the HCC827 cell by the in vitro culture?drug sensitive test of the thiazolylblu and flow cytometry, to assay the tumor cell rejection and cell line. Control group 1: We use the gemcitabine to investigate the HCC827 cell by the in vitro culture?drug sensitive test of the thiazolylblu and flow cytometry, to assay the tumor cell inhibition and cell line. Control group 2: We use the cinobufotalin to test the HCC827 cell by the in vitro culture?drug sensitive test of the thiazolylblu and flow cytometry,to assay the tumor cell inhibition and cell line. Results: First:we can get the outcome of the gemcitabine in curing human NSCLC,which is the high drug level, the high cancericidal and up suppression ratio,the low survival quotiety. For example,within the scope and range of 0.0025 to 0.04 u M, about 10% of the cell survival rate decreased,while within the range of 0.08 to 0.32 u M about 20% cell survival rate decreased. Then, we can get the influence of the cell line by the gemcitabine in curing human NSCLC, which can promote cell DNA synthesis and cell mitosis( cell proliferation),but it induced the apoptosis of cells, resulting the decrease in the number of cells. Second:we can get the result of the cinobufotalin in curing human NSCLC in a concentration-dependent way. That is the high drug level, the less cells,but there is a lack of number of obviously killed cells. Furthermore,the cinobufotalin individual treatment can promote cells into DNA synthesis period(S), but block cell division in G2 / M phase, which result in that mitotic cells can't accomplish completely, and there is no obvious difference compared with control group, so the overall effect is reducing the number of cells. Third,both the cinobufotalin(20 to 40, 80, 160 times dilution) and gemcitabine(0.04 u M)drug use can reduce HCC827 cell vitality, and the cinobufotalin combination gemcitabine can further reduce the HCC827 cell vitality, improving cell survival inhibition rate. Then,the treatmen of cinobufotalin conjoining with gemcitabine can inhibit cells into DNA synthesis period(S), but does not affect cell mitosis(G2 / M phase),However, it still strongly promotes the apoptosis of cells,which leads to the overall effect of the decrease in the number of cells and inhibition of cell growth state. Conclusion:First:we can get the result of thecinobufotalin with gemcitabine in treating NSCLC,which can further reduce HCC827 cell vitality and improve cell survival inhibition rate in the way. Second,we can get the influence of the cell line by gemcitabine and thecinobufotalin which gets the effect of the decrease in the number of cells and inhibition of cell growth state. Third,it offers the theoretical accord for the cinobufotalin to become the assistanrt medicament in treating human NSCLC by this experience.